75
At the largest pharma and biotech meeting ever in Barcelona, CPhI organiser UBM presented several huge growth opportunities by 2021 within its annual report: A first trend is identification of new targets using real world data and massively parallel computing to find context-dependent biomarker/target patterns in clinical samples affects both big pharma and biotech drug development. However, current analysis suggest that genome-wide association studies show European bias as most studies in the last decade were carried out there.
The second one was named as individualisation of solid dosage forms with defined drug release profile through 3D…